Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2529894 | PMC |
| http://dx.doi.org/10.1136/pgmj.25.279.3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dr. Thomas Francis Jr.: A Legacy of Vaccine Innovation and Public Health Advancement.
Cureus
November 2024
Central Research Facility, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed to Be University), Pune, IND.
Dr. Thomas Francis Jr. was an American physician, virologist, and epidemiologist who was a professor of epidemiology at the University of Michigan from 1941 to 1969.
View Article and Find Full Text PDFRecent Advances in Designing Adeno-Associated Virus-Based Vaccines Against Viral Infections.
Pharmaceutics
October 2024
Wits/SAMRC Antiviral Gene Therapy Research Unit, Infectious Diseases and Oncology Research Institute (IDORI), Faculty of Health Sciences, University of the Witwatersrand, Parktown 2193, South Africa.
Article Synopsis
- * Next-generation vaccines like mRNA and viral vector technologies have emerged, with adenoviral vector-based vaccines showing a stronger antibody response than mRNA vaccines for COVID-19 but having some severe adverse events.
- * Adeno-associated viral vectors have been less popular due to their weaker immune response but are now being reconsidered for use as antiviral vaccines, and this review will highlight recent advancements in this area.
Effect of a campaign with oral polio vaccine on general health: A cluster-randomised trial in rural Guinea-Bissau.
J Infect
December 2024
Bandim Health Project, Bissau, Guinea-Bissau; Bandim Health Project, Research Unit OPEN, Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Electronic address:
Objectives: To investigate in a cluster-randomised trial whether a campaign with oral polio vaccine (C-OPV) reduced mortality and morbidity.
Methods: We randomised 222 village clusters under demographic surveillance to an intervention (health check and C-OPV) or control group (health check only). Children aged 0-8 months were eligible.
Use of virus-like particles and nanoparticle-based vaccines for combating picornavirus infections.
Vet Res
September 2024
State Key Laboratory for Animal Disease Control and Prevention, CollegeofVeterinaryMedicine, Lanzhou UniversityLanzhou Veterinary Research InstituteChinese Academy of Agricultural Sciences, Lanzhou, 730000, China.
Article Synopsis
- * Virus-like particle (VLP) and nanoparticle (NP) vaccines are innovative approaches that utilize self-assembling viral proteins or nanomaterials to present viral antigens and provoke strong immune responses.
- * The review discusses advancements in VLP and NP vaccine development against various picornaviruses, emphasizing the need for ongoing research to improve their effectiveness, stability, and interaction with the immune system.
Case Study: Contribution of Extended Sequencing and Phylogeographic Analysis in the Investigation of Measles Outbreaks in Tunisia in 2019.
Vaccines (Basel)
September 2024
Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Pasteur Institute of Tunis, University Tunis El Manar (UTM), Tunis 1002, Tunisia.
Despite the availability of an effective vaccine for several decades, the measles virus continues to spread worldwide. From 2018 to 2019, several countries experienced large measles outbreaks with genotype B3, including Tunisia. We analyzed 66 samples collected from serologically confirmed measles cases during this outbreak.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!